Henrik Watz, MD, PhD, is the chief investigator and author of trial results for EpiEndo’s clinical trial of glasmacinal (EP395). Results indicated that glasmacinal reduced neutrophilic inflammation in COPD patients without any detectable impact on the lung microbiome, supporting preclinical findings of reduced antimicrobial resistance potential.
Dr. Watz in the accompanying press release: “The data are encouraging and show that glasmacinal has the potential to become an important treatment option for patients with frequent exacerbations, especially those with neutrophilic inflammation for whom there are currently limited treatment options.”
Read the ERJ Open Research article: https://publications.ersnet.org/content/erjor/early/2025/11/13/2312054100782-2025
Read the full press release: https://www.globenewswire.com/news-release/2025/12/08/3201212/0/en/EpiEndo-Pharmaceutical-s-ERJ-Open-Research-article-reports-first-clinical-trial-of-glasmacinal-EP395-in-COPD-patients.html
